Palisade Bio Commences Dosing in First Ulcerative Colitis Patient Cohort in Ongoing Phase 1a/b Study of PALI-2108
Portfolio Pulse from
Palisade Bio has started dosing the first cohort of ulcerative colitis patients in its ongoing Phase 1a/b study of PALI-2108. Preliminary data from previous cohorts indicate the drug's safety and tolerability.
March 14, 2025 | 12:45 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Palisade Bio has initiated dosing in a new patient cohort for its PALI-2108 study, with positive safety and tolerability data from earlier cohorts.
The initiation of dosing in a new cohort and positive preliminary data from earlier cohorts suggest progress in the development of PALI-2108, which could positively impact Palisade Bio's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100